Ratings MannKind Corporation

Equities

MNKD

US56400P7069

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
4.26 ^USD	+0.71%		+3.65%	+17.03%

Apr. 29	MannKind Gets FDA Approval to Begin Phase 3 Trial of Lung Disease Treatment	MT
Apr. 29	MannKind Gets FDA Clearance for Clofazimine IND Application	DJ

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company benefits from high valuations in earnings multiples.
The company's enterprise value to sales, at 3.48 times its current sales, is high.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
MANNKIND CORPORATION	+17.03%	1.15B	C+
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	102B	B+
REGENERON PHARMACEUTICALS, INC.	+1.62%	96.29B	B+
ARGENX SE	+1.46%	22.18B	B
BIONTECH SE	-16.67%	21.2B	B+
GENMAB A/S	-8.68%	18.31B	A-
WUXI APPTEC CO., LTD.	-38.74%	17.38B	A-
BEIGENE, LTD.	-13.21%	16.36B	B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.97B	C+
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes